Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy candidate giroctocogene fitelparvovec, the big pharma has decided to end development and commercialization of Beqvez (fidanacogene elaparvovec-dzkt), its hemophilia B gene therapy approved in the US in April 2024. The company told Scrip that it does not plan to develop or commercialize any other adeno-associated virus (AAV)-based gene therapies.
Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market
Product Saw Zero Sales Since April Approval
Pfizer cited many reasons for ending sales of hemophilia B gene therapy Beqvez, including a lack of patient and doctor interest. The company no longer plans to develop AAV gene therapies.
More from Strategy
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.